364 shares of its common share at a cost to the general public of $2.

BioPharmX announces closure of announced underwritten public offering of common share previously BioPharmX Company today announced the closing of its previously announced underwritten community offering of 3,636,364 shares of its common share at a cost to the general public of $2.75 per share http://tadalift.net/nasty-male-problem.htm tadalift.net . BioPharmX offers granted the underwriters a 30-day substitute for purchase up to 545,454 extra shares of common share at the general public offering price. Furthermore, Korea Investment Companions Overseas Expansion System Fund, a preexisting stockholder, has decided to buy 1,081,081 shares of common share from BioPharmX in an exclusive placement regarding the the effective uplisting of the organization's common share to the NYSE MKT.

after prostate surgery

Bio-Route to initiate BP-100-1.01 Stage I trial for treatment of two types of breasts cancer Bio-Route Holdings, Inc., , a biotechnology firm creating a liposomal delivery technology for nucleic acid cancer tumor drugs, today announced it really is initiating advancement of its lead malignancy drug BP-100-1.01 to take care of triple negative breast malignancy and inflammatory breasts cancer , two cancers seen as a formation of intense tumors and relatively high mortality rates. Bio-Path is currently analyzing Liposomal Grb-2 in a Phase I medical trial as a systemic treatment for bloodstream cancers including severe myeloid leukemia , chronic myelogenous leukemia , severe lymphoblastic leukemia and myelodysplastic syndrome .

Related Articles

Other Articles from "proctology":